评估新一代酪氨酸激酶抑制剂在治疗具有获得性激酶结构域突变的癌症中的潜在作用。 - Suppr

Assessing the potential role of next generation tyrosine kinase inhibitors in the treatment of cancers with acquired kinase domain mutations.

作者信息

Thirumal Raj A, Patil Shankargouda, Ranadheer R, Chandini R

机构信息

Department of Oral Pathology and Microbiology, Sri Venkateswara Dental College and Hospital, Thalambur, Chennai 600130, India.

Department of Maxillofacial Surgery and Diagnostic Sciences, Division of Oral Pathology, College of Dentistry, Jazan University, Jazan, Saudi Arabia.

出版信息

Oral Oncol. 2017 Oct;73:172. doi: 10.1016/j.oraloncology.2017.09.001.

DOI:10.1016/j.oraloncology.2017.09.001

PMID:28923250

Abstract

摘要

相似文献

Assessing the potential role of next generation tyrosine kinase inhibitors in the treatment of cancers with acquired kinase domain mutations.

Oral Oncol. 2017 Oct;73:172. doi: 10.1016/j.oraloncology.2017.09.001.

Heritable resistance to tyrosine kinase inhibitors.

Clin Adv Hematol Oncol. 2014 Jul;12(7):454-7.

[Tyrosine kinases as targets of cancer therapy: from disbelief to Lazarus responses].

Duodecim. 2012;128(21):2261-8.

Acquired resistance to tyrosine kinase inhibitors during cancer therapy.

Curr Opin Genet Dev. 2008 Feb;18(1):73-9. doi: 10.1016/j.gde.2008.01.004. Epub 2008 Mar 5.

BCR-ABL kinase domain mutations in tyrosine kinase inhibitors-naïve and -exposed Southeast Asian chronic myeloid leukemia patients.

Exp Mol Pathol. 2012 Apr;92(2):259-65. doi: 10.1016/j.yexmp.2012.01.007. Epub 2012 Jan 31.

Stocking oncology's medicine cabinet.

Science. 2017 Mar 17;355(6330):1142-1143. doi: 10.1126/science.355.6330.1142.

Larotrectinib followed by selitrectinib in a novel fusion undifferentiated pleomorphic sarcoma.

J Oncol Pharm Pract. 2021 Mar;27(2):485-489. doi: 10.1177/1078155220938849. Epub 2020 Jul 21.

Tyrosine kinases as targets for cancer therapy.

N Engl J Med. 2005 Jul 14;353(2):172-87. doi: 10.1056/NEJMra044389.

Best Use of the Tyrosine Kinase Inhibitors in Progressive Differentiated Thyroid Cancer: Discussion.

Clin Adv Hematol Oncol. 2016 May;14(5 Suppl 9):12-3.

The second generation of BCR-ABL tyrosine kinase inhibitors.

Int J Hematol. 2006 May;83(4):294-300. doi: 10.1532/IJH97.06025.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Assessing the potential role of next generation tyrosine kinase inhibitors in the treatment of cancers with acquired kinase domain mutations.

Oral Oncol. 2017 Oct;73:172. doi: 10.1016/j.oraloncology.2017.09.001.

Heritable resistance to tyrosine kinase inhibitors.

Clin Adv Hematol Oncol. 2014 Jul;12(7):454-7.

[Tyrosine kinases as targets of cancer therapy: from disbelief to Lazarus responses].

Duodecim. 2012;128(21):2261-8.

Acquired resistance to tyrosine kinase inhibitors during cancer therapy.

Curr Opin Genet Dev. 2008 Feb;18(1):73-9. doi: 10.1016/j.gde.2008.01.004. Epub 2008 Mar 5.

BCR-ABL kinase domain mutations in tyrosine kinase inhibitors-naïve and -exposed Southeast Asian chronic myeloid leukemia patients.

Exp Mol Pathol. 2012 Apr;92(2):259-65. doi: 10.1016/j.yexmp.2012.01.007. Epub 2012 Jan 31.

Stocking oncology's medicine cabinet.

Science. 2017 Mar 17;355(6330):1142-1143. doi: 10.1126/science.355.6330.1142.

Larotrectinib followed by selitrectinib in a novel fusion undifferentiated pleomorphic sarcoma.

J Oncol Pharm Pract. 2021 Mar;27(2):485-489. doi: 10.1177/1078155220938849. Epub 2020 Jul 21.

Tyrosine kinases as targets for cancer therapy.

N Engl J Med. 2005 Jul 14;353(2):172-87. doi: 10.1056/NEJMra044389.

Best Use of the Tyrosine Kinase Inhibitors in Progressive Differentiated Thyroid Cancer: Discussion.

Clin Adv Hematol Oncol. 2016 May;14(5 Suppl 9):12-3.

The second generation of BCR-ABL tyrosine kinase inhibitors.

Int J Hematol. 2006 May;83(4):294-300. doi: 10.1532/IJH97.06025.

Assessing the potential role of next generation tyrosine kinase inhibitors in the treatment of cancers with acquired kinase domain mutations.

作者信息

Thirumal Raj A, Patil Shankargouda, Ranadheer R, Chandini R

机构信息

Department of Oral Pathology and Microbiology, Sri Venkateswara Dental College and Hospital, Thalambur, Chennai 600130, India.

Department of Maxillofacial Surgery and Diagnostic Sciences, Division of Oral Pathology, College of Dentistry, Jazan University, Jazan, Saudi Arabia.

出版信息

Oral Oncol. 2017 Oct;73:172. doi: 10.1016/j.oraloncology.2017.09.001.

DOI:10.1016/j.oraloncology.2017.09.001

PMID:28923250

Abstract

摘要

Assessing the potential role of next generation tyrosine kinase inhibitors in the treatment of cancers with acquired kinase domain mutations.

作者信息

机构信息

出版信息

相似文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

Assessing the potential role of next generation tyrosine kinase inhibitors in the treatment of cancers with acquired kinase domain mutations.

作者信息

机构信息

出版信息